balsalazide disodium (Colazal) vs mesalamine (Asacol HD)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: Aminosalicylate · full Ulcerative Colitis pipeline
balsalazide disodium (Colazal)
Rights held by Bausch Health; US product discontinued
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
mesalamine (Asacol HD)
Rights held by AbbVie
NCT00577473 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 301 participants, comparing mesalamine 4.8 g/day with mesalamine 2.4 g/day. The primary clinical and sigmoidoscopy-based treatment-success endpoint was not significantly different between doses (p=0.4411), so the results provide well-controlled but inconclusive evidence that the higher dose is more effective.
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | balsalazide disodium (Colazal) | mesalamine (Asacol HD) |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not posted · NCT00548574 |
| Clinical remission (maintenance) | —Not reported | —Not posted · NCT00548574 |
| Clinical response (induction) | —Not reported | —Not posted · NCT00548574 |
| Endoscopic improvement (induction) | —Not reported | —Not posted · NCT00548574 |
| Corticosteroid-free remission (maintenance) | —Not reported | —Not posted · NCT00548574 |
Clinical remission (induction)
- balsalazide disodium (Colazal)
- —Not reported
- mesalamine (Asacol HD)
- —Not posted · NCT00548574
Clinical remission (maintenance)
- balsalazide disodium (Colazal)
- —Not reported
- mesalamine (Asacol HD)
- —Not posted · NCT00548574
Clinical response (induction)
- balsalazide disodium (Colazal)
- —Not reported
- mesalamine (Asacol HD)
- —Not posted · NCT00548574
Endoscopic improvement (induction)
- balsalazide disodium (Colazal)
- —Not reported
- mesalamine (Asacol HD)
- —Not posted · NCT00548574
Corticosteroid-free remission (maintenance)
- balsalazide disodium (Colazal)
- —Not reported
- mesalamine (Asacol HD)
- —Not posted · NCT00548574
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
balsalazide disodium (Colazal): no structured comparison results are available for Ulcerative Colitis.
mesalamine (Asacol HD): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: balsalazide disodium (Colazal)'s landscape · mesalamine (Asacol HD)'s landscape